Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.

Acta pharmacologica Sinica - 1 Mar 2014

Yang Li, Shi Li-ping, Chen Hai-jun, Tong Xian-kun, Wang Gui-feng, Zhang Yang-ming, Wang Wen-long, Feng Chun-lan, He Pei-lan, Zhu Feng-hua, Hao You-hua, Wang Bao-ju, Yang Dong-liang, Tang Wei, Nan Fa-jun, Zuo Jian-ping

Abstract excerpt

AIM: To investigate the action of isothiafludine (NZ-4), a derivative of bis-heterocycle tandem pairs from the natural product leucamide A, on the replication cycle of hepatitis B virus (HBV) in vitro and in vivo. METHODS: HBV replication cycle was monitored in HepG2.2.15 cells using qPCR, qRT-PC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Multiple, Viral
Share to Ducks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hep G2 Cells

Share to Hepatitis B virus

Share to Hepatitis, Viral, Animal

Share to Nucleocapsid

Share to Thiazoles

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 24487969
DOI: 10.1038/aps.2013.175
PMCID: PMC4647886

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24487969-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.PMID 24487969Read ↗

Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.Semantic proximity Read ↗

The progress of molecules and strategies for the treatment of HBV infectionSemantic proximity Read ↗

Progress and Prospects of Anti-HBV Gene Therapy DevelopmentSemantic proximity Read ↗

Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?Semantic proximity Read ↗

Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNASemantic proximity Read ↗

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents.Semantic proximity Read ↗

Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731Semantic proximity Read ↗

Molecular therapeutics of HBV.Semantic proximity Read ↗

Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein.Semantic proximity Read ↗

Safety Assessment and Evaluation of Novel Thiourea Derivatives as AntiviralsSemantic proximity Read ↗

Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates.Semantic proximity Read ↗

Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.